Certain synthetic retinoid-related molecules induce apoptosis in cancer cells through a novel mechanism of retinoid action that is independent of the nuclear retinoid receptors. These compounds target protein kinases and protein phosphatases to trigger signal transduction pathways that lead to apoptosis. Whereas retinoid agonists such as CD437 activate stress kinases via inhibition of the phosphatase MKP-1, the retinoid antagonist MX781 inhibits the survival kinase IKK. These retinoid-mediated signaling pathways converge at the mitochondria, where they cause the release of cytochrome c and subsequent Apaf-1-dependent activation of caspases. Identification of the retinoid targets that mediate their apoptotic activity will enhance our understanding of the mechanism of this novel retinoid action, to allow appropriate optimization of currently available compounds to advance into the clinic as novel anticancer agents.
Retinoids are natural and synthetic vitamin A derivatives and analogs that regulate many important biological processes, including vision, morphogenesis, differentiation, growth, metabolism, and homeostasis. Certain synthetic retinoids have also been found to be potent inducers of apoptosis. While a wealth of detailed information has been obtained on the role of 11-cis retinaldehyde in the phototransduction process, other major active vitamin A derivatives, especially all-transretinoic acid (tRA) and 9-cis-retinoic acid (9-cis-RA), function as hormone-like signaling molecules, regulating biological processes by binding to specific nuclear receptors, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). The antiproliferation activity observed for tRA was found to be mostly due to growth inhibition and the induction of differentiation. Mechanistically, growth inhibition by natural retinoids appears to result from the inhibition of the transcription factor AP-1, that is, inhibition of a growth signal. Although apoptosis induction has been reported for tRA in some cell lines (Liu et al., 1996) , this effect is weak and is only seen when these compounds are used at supraphysiological concentrations. As a consequence, natural retinoids have not been developed as anticancer agents, with the exception of tRA, which is effective for the treatment of acute promyelocytic leukemia, where tRA functions as a differentiation agent (Degos and Wang, 2001 ). However, several classes of synthetic retinoic acid analogs have been identified as potent inducers of apoptosis. A critical question has been whether these molecules induce apoptosis by targeting the same nuclear retinoid receptors or whether apoptosis induced by these molecules involves binding to nonnuclear retinoid receptor targets. We will review here data pointing to novel signaling pathways activated by these compounds and discuss putative targets for apoptosis-inducing retinoids.
In general, the apoptosis-inducing retinoids can be divided into three types of chemically distinct classes: (i) the natural compound anhydroretinol (AR); (ii) the synthetic analog 4-hydroxyphenyl-retinamid (4-HPR); and (iii) naphthoic acid derivatives with an adamantyl group (see Table 1 ).
AR is a vitamin A metabolite that, contrary to 14-hydroxy-retro-retinol, induces oxidative stress, F-actin reorganization, and apoptosis in the absence of chromatin condensation and DNA cleavage (O'Connell et al., 1996; Chen et al., 1999; Korichneva and Hammerling, 1999) . The fact that AR does not bind known retinoid receptors and that AR-induced apoptosis is blocked by herbimycin A (O'Connell et al., 1996) suggested that AR could function via protein kinases probably located in the cytoplasma. The search for an AR and 14-hydroxy-retro-retinol receptor resulted in the discovery of protein kinase C and c-Raf as receptors for these vitamin A metabolites (Imam et al., 2001; Hoyos et al., 2002) . Interestingly, while AR enhanced hydrogen peroxide-mediated activation of protein kinase C, it inhibited UV-dependent activation of c-Raf. Whether AR binding to these kinases and modulation of their activity are essential for the induction of apoptosis remains unclear, since tRA and retinol also bind these targets in the absence of a cytotoxic effect (Hoyos et al., 2000 (Hoyos et al., , 2002 . Thus, the apoptotic pathway activated by these natural compounds appears to involve protein kinases but needs to be further elucidated; it is, however, clearly independent of retinoid receptors.
4-HPR, also known as fenretinide, has been considered a cancer prevention agent and has been extensively tested in clinical trials. It induces apoptosis in a variety (Delia et al., 1993; Hsieh et al., 1995; Kalemkerian et al., 1995; Ponzoni et al., 1995; Fanjul et al., 1996; Wang and Phang, 1996; Piedrafita and Pfahl, 1997) possibly through the generation of reactive oxygen species (Delia et al., 1995 (Delia et al., , 1997 Oridate et al., 1997; Suzuki et al., 1999) . 4-HPR is a selective activator of RARg (Fanjul et al., 1996) , and retinoid receptors appear to be involved in 4-HPR-induced apoptosis in certain cell types (Delia et al., 1993; Sun et al., 1999a) . Although 4-HPR induces oxidative stress, antioxidants do not always protect cancer cells against 4-HPRinduced apoptosis (Sun et al., 1999a) . This suggests that multiple mechanisms are responsible for the induction of apoptosis by fenretinide (Wu et al., 2001) , including the production of nitric oxide, downregulation of cyclooxygenase-2, and elevated ceramide levels (Merritt et al., 2001; Wang et al., 2001; Erdreich-Epstein et al., 2002; Simeone et al., 2002) .
The naphthoic acid-adamantyl compounds and structurally related molecules comprise a series of molecules that include the RARg-selective agonists CD437 and MX3350-1 as well as the antagonist MX781, which, because of their unusual biological activities, have also been termed as retinoid-related molecules (RRMs). In particular, CD437 and MX3350-1, as well as several related derivatives, were found to act as potent apoptosis inducers in a variety of cancer cell lines (Lu et al., 1997; Piedrafita and Pfahl, 1997; Bayon et al., 2003;  and references therein), including RA-resistant cells (Hsu et al., 1997) , and this effect is not inhibited by retinoid antagonists (Sun et al., 2000; Bayon et al., 2003) . This indicated that CD437-induced apoptosis is independent of the retinoid receptors. Moreover, CD437-induced apoptosis was found not to require gene transcription or protein synthesis in human leukemia cells, suggesting a novel mechanism of action for these RRMs (Piedrafita and Pfahl, 1997; Mologni et al., 1999; Zhang et al., 1999) . A different mechanism of action may be involved in certain cell lines derived from solid tumors, in which upregulation of GADD45, AP-1, Nur77, c-Myc, p53, and p21 (Waf/CIP1) has been demonstrated to play a role in CD437-induced apoptosis (Li et al., 1998 (Li et al., , 2000 Rishi et al., 1999; Sakaue et al., 1999; Sun et al., 1999b, c) .
Similar to other chemotherapeutic drugs, the selective RRMs induce apoptosis through the intrinsic pathway, via mitochondrial damage. Thus, CD437 increases the levels of reactive oxygen species concurrent with mitochondrial permeability transition (Hail et al., 2001) , and several MPT inhibitors block CD437-induced apoptosis (Marchetti et al., 1999) . Moreover, CD437 can directly target the mitochondria and induce the release of proapoptotic factors from isolated mitochondria (Marchetti et al., 1999; Belzacq et al., 2001 ). When we used specific caspase inhibitors that prevent the activation of caspases, the induction of DNA fragmentation was also inhibited, but not the release of cytochrome c, supporting that RRMs induce apoptosis in a caspase-dependent manner (Ortiz et al., 2001; . Further evidence , 2003) . Caspase 2 contains a large prodomain and was believed to exert a role in the final steps of apoptosis (Slee et al., 1999) . However, recent evidence indicated that caspase 2 can induce the release of mitochondrial proteins (Guo et al., 2002; Paroni et al., 2002) , and it is proposed to initiate stress-induced apoptosis upstream of mitochondrial damage (Lassus et al., 2002) . Thus, our data show that RRMs with agonist or antagonist activity utilize different pathways (caspase 2-dependent or independent) to induce apoptosis, which converge in the mitochondria. In addition to caspase-dependent apoptosis, the selective RRMs can induce caspase-independent cell death (Adachi et al., 1998; , indicating that other proteases can also be activated by the RRMs to effectively kill cancer cells. Several types of proteases are known to induce apoptosis, including cathepsins, calpains, and granzymes (Johnson, 2000) . Thus, cathepsin D has been reported to mediate CD437-induced apoptosis in HL-60 cells (Zang et al., 2001 ), although we found no evidence of cathepsins being involved in RRM-induced apoptosis in Jurkat T cells .
The primary target or targets for RRM-induced apoptosis can be delineated by back tracking the apoptosis-signaling pathway. Since CD437 can induce apoptosis in the absence of a nucleus (Marchetti et al., 1999) , the prime mediators of RRM action could reside in the cytosol, as suggested for AR (see above). We found that the agonist RRMs induce a strong and sustained activation of JNK and p38 stress kinases, which is independent of the activation of caspases (Ortiz et al., 2001) . Activation of JNK and p38 kinases by CD437 has also been previously reported (Zhang et al., 1999; Ponzanelli et al., 2000) . Interestingly, we observed that JNK and p38 activation by the RRMs was not prevented by caspase inhibitors, and inhibition of p38 kinase with the p38 selective inhibitor SB203580 had no effect on RRM-induced apoptosis. In contrast, interference with both JNK and p38 pathways by PD169316 completely blocked all signs of apoptosis induced by MX2870-1 and other agonists, including the release of cytochrome c (Ortiz et al., 2001) . These data indicate that activation of JNK is critical for RRM-induced apoptosis, as proposed for other stress signals (Tournier et al., 2000) . Activation of AP-1 by the agonist RRMs is not observed in Jurkat cells (our unpublished observations), consistent with JNK-induced apoptosis being independent of transcription (Tournier et al., 2000) . This is in contrast with previous observations in lung cancer cell lines, in which cJun transcriptional activity seems necessary for the induction of apoptosis by CD437 (Li et al., 1998) . Our data suggest that JNK could function via phosphorylation of proteins other than cJun. In fact, JNK has been shown to translocate into the mitochondria during apoptosis, where it phosphorylates and inactivates antiapoptotic proteins such as Bcl-2 and BclX L (Maundrell et al., 1997; Yamamoto et al., 1999) , whereas phosphorylation of Bad enhances its proapoptotic activity (Donovan et al., 2002) .
In Figure 1 , we schematically show the JNKdependent apoptosis pathway. Activation of JNK is regulated on the one hand by the MAP kinase pathways that, in response to many extra-and intracellular signals, participate in a phosphorylation cascade that leads to JNK activation. Major modulators of this pathway are the dual-specificity phosphatases (Camps et al., 1999) , in particular MKP-1, which dephosphorylate JNK. Thus, inhibition of MKP-1 can lead to JNK activation. The question therefore arises as to whether MKP-1 could be the direct target for certain RRMs such as CD437, MX3350-1, and MX2870-1. As pointed out (see Table 1 ), these compounds contain naphtoic acid groups. Naphtoic acid groups have been observed and proposed to function as anchoring groups for small molecules on several families of proteins, including nuclear receptors, kinases, and phosphatases. Thus, Figure 1 Schematic cartoon showing the JNK/apoptosis induction pathways activated by selective RRMs. RAR agonists, including CD437 and MX2870-1, produce a strong activation of JNK, probably due to the direct inhibition of MKP-1. JNK activation is known to phosphorylate various members of the Bcl-2 family and provoke the release of proapoptotic factors from the mitochondria, engaging the subsequent activation of caspases and apoptosis. The RAR antagonist MX781 is a strong inhibitor of IKK, which signals activation of NFkB and upregulation of antiapoptotic products. Thus, inhibition of IKK results in reduced levels of IAPs and the consequent activation of caspases besides binding to RARs, CD437, MX3350-1, and related compounds could also interact with other classes of proteins. We have recently investigated whether CD437 can indeed inhibit the MKP-1 phosphatase. In Figure 2 , we compare the inhibition of MKP-1 by CD437 and the MKP-1 inhibitor MX7091. Indeed, CD437 shows effective inhibition of MKP-1 in an in vitro enzyme assay. It is therefore likely that CD437 and structurally related RRMs induce the JNK apoptosis pathway by directly binding to and inhibiting the MKP-1 phosphatase. MKP-1 has now been found to be overexpressed in a number of tumors (Magi-Galluzzi et al., 1997; Bang et al., 1998; Denkert et al., 2002; Wang et al., 2003) , especially in NSCLC, prostate and ovarian cancers, in which MKP-1 expression correlates with resistance to apoptosis and poor prognosis (MagiGalluzzi et al., 1997; Denkert et al., 2002; Vicent et al., 2002) . It will be of interest to see whether cell lines resistant to CD437 can be found, which overexpress MKP-1 or show other defects in the JNK apoptosis pathway.
Are there other targets that these compounds can interact with? We recently observed that the retinoid antagonist MX781 and certain agonist RRMs can inhibit IkBa kinase (IKK) signaling through direct binding to and inhibition of the kinase . Activation of IKK results in the transcriptional activation of NFkB and subsequent upregulation of several genes that encode inhibitors of apoptosis, including IAPs, cFLIP, TRAF-1, -2, and the Bcl-2 family member Bfl-1 (Karin et al., 2002) . Constitutively active IKK correlates with high levels of NFkB transcriptional activity and enhanced chemoresistance in several types of cancer cells, including melanoma cells (Yang and Richmond, 2001) , and inhibition of NFkB activity is sufficient to induce apoptosis and enhance the anticancer activity of certain drugs . Thus, IKK can also be a direct target for some of the RRMs, consistent with their structures.
In summary, retinoids have been found to effect and regulate many important biological mechanisms including apoptosis. While most of the classical retinoid activities can be ascribed to retinoid regulation of nuclear retinoid receptor activities, apoptosis appears to be induced through interactions with other targets (see Figure 1) , including the MKP-1 phosphatase and IKK to which only the synthetic apoptosis-inducing retinoids bind but not the natural compounds. 
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Concentration µM Figure 2 In vitro inhibition of MKP-1 by CD437. A measure of 50 U of recombinant MKP-1 (Upstate) was preincubated with CD437 or MX7091 for 10 min in an assay buffer containing 100 mM Tris-HCl, pH 8.2, 40 mM NaCl, 1 mM DTT, and 20% glycerol. Reactions were initiated by addition of the substrate 3-Omethylfluorescein phosphate at a final concentration of 160 mM.
The sample absorbance was measured at 477 nm after 120 min and the percentage of inhibition was determined by comparison with the vehicle control
